Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2014

La inhibición selectiva de la tirosina quinasa esplénica (SYK) con un nuevo inhibidor de molécula pequeña biodisponible oralmente, RO9021, afecta diferentes respuestas inmunes innatas y adaptativas: implicaciones para los inhibidores de la SYK en el tratamiento de enfermedades autoinmunes

Arthritis Research and Therapy 2013 15:R146

Liao C,

Hsu J,

Kim Y et al

Spleen tyrosine kinase (SYK) has already been described as a potential therapeutic target for the treatment of autoimmune diseases. Previously the SYK inhibitor fostamatinib was in clinical development for the treatment of rheumatoid arthritis, but has since been suspended. However, investigation into SYK inhibition continues with RO2091, a novel ATP-competitive inhibitor of SYK with reasonable selectivity, potency and oral bioavailability which has been shown to suppress various innate and adap...

Keywords:

August 2013

Enfoque en el eje SYK-BTK para el tratamiento de trastornos inmunológicos y hematológicos: progreso reciente y perspectivas terapéuticas

Pharmacol Ther. 2013 May; 138(2):294–309

Tan SL,

Liao C,

Lucas MC,

et al

This review focuses on targeting spleen tyrosine kinase (SYK) and Bruton’s tyrosine kinase (BTK) inhibitors as potential immunomodulatory agents for the treatment of autoimmune and inflammatory disorders with SYK inhibition showing encouraging efficacy in patients with RA. The paper describes the role of SYK and BTK in several therapy areas including autoimmune diseases, allergic inflammatory disorders and haematological cancers as well as their role in innate immunity and regulators of adaptive...